Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. 2021

Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
1Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan.

In the CASPIAN trial, durvalumab + chemotherapy demonstrated significant improvements in overall survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer (SCLC). We aimed to assess the cost-effectiveness of durvalumab in patients with extensive-stage SCLC from the US healthcare system perspective. A comprehensive Markov model was adapted to evaluate cost and effectiveness of durvalumab combination versus platinum/etoposide alone in the first-line therapy of extensive-stage SCLC based on data from the CASPIAN study. The main endpoints included total costs, life years (LYs), quality-adjusted life-years (QALYs), and incremental cost-e-ectiveness ratios (ICERs). Model robustness was assessed with sensitivity analysis, and additional subgroup analyses were also performed. Durvalumab + chemotherapy therapy resulted in an additional 0.27 LYs and 0.20 QALYs, resulting in an ICER of $464,711.90 per QALY versus the chemotherapy treatment. The cost of durvalumab has the greatest influence on this model. Subgroup analyses showed that the ICER remained higher than $150,000/QALY (the willingness-to-pay threshold in the United States) across all patient subgroups. Durvalumab in combination with platinum/etoposide is not a cost-effective option in the first-line treatment of patients with extensive-stage SCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D010984 Platinum A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae". Platinum Black
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000094703 Cost-Effectiveness Analysis A method of comparing the cost of a program with its expected outcomes that are qualitative in nature. Cost effectiveness compares alternative ways to achieve a specific set of results. Cost Effectiveness,Cost Effectiveness Ratio,Analysis, Cost-Effectiveness,Cost Effectiveness Analysis,Cost Effectiveness Ratios,Effectiveness Ratio, Cost,Effectiveness, Cost,Ratio, Cost Effectiveness
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D055752 Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA). Oat Cell Carcinoma of Lung,Carcinoma, Small Cell Lung,Oat Cell Lung Cancer,Small Cell Cancer Of The Lung,Small Cell Lung Cancer

Related Publications

Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
April 2019, Lung cancer (Amsterdam, Netherlands),
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
January 2022, Frontiers in immunology,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
January 2022, Expert review of pharmacoeconomics & outcomes research,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
January 2020, Frontiers in oncology,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
January 2021, PloS one,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
April 2024, Medicine,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
June 2022, Clinical drug investigation,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
December 2019, Chinese medical journal,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
December 2018, The New England journal of medicine,
Dong Ding, and Huabin Hu, and Shuosha Li, and Youwen Zhu, and Yin Shi, and Mengting Liao, and Jin Liu, and Xu Tian, and Aiting Liu, and Jin Huang
June 2021, International journal of clinical oncology,
Copied contents to your clipboard!